Breaking news
European Commission Approves BeiGene's Tevimbra, Chemo in First-Line Gastric, Esophageal Cancers
The EC considered the treatment's activity in patients with advanced, PD-L1-positive esophageal and gastric cancers in the RATIONALE-305 and -306 trials.
Anocca Seeking EMA Permission to Test TCR T-Cell Therapy in KRAS-Mutated Pancreatic Cancer
The Swedish firm plans to expand the VIDAR-1 umbrella trial to study additional KRAS-targeting product candidates in the future.
Sarepta Licenses Clinical, Preclinical siRNA Candidates From Arrowhead, Enters Discovery Deal
Sarepta will pay Arrowhead Pharmaceuticals $500 million upfront, make a $325 million equity investment, plus pay $250 million over five years, and more.
Advanced Genomics APAC, 3BIGS Partner on Cancer Testing in Asia-Pacific
The firms will bring together Advanced Genomics APAC's genomic profiling workflow and 3BIGS's bioinformatics capabilities.
Roche's Tiragolumab, Tecentriq Combo Misses Overall Survival Endpoint in PD-L1 Positive NSCLC Trial
The addition of tiragolumab to Tecentriq in patients with advanced PD-L1-high NSCLC failed to improve overall survival in a Phase III trial.
Eisai to Cover APOE Genotyping as Part of Dementia Research Registry in Japan
Eisai and the National Center of Neurology and Psychiatry in Tokyo will study the link between APOE genotype and safety and efficacy of Leqembi.
AstraZeneca to Share With Regulators Results From Truqap Trial in PTEN-Altered Prostate Cancer
Patients with PTEN-deficient prostate cancer showed improvement in progression-free survival on Truqap plus standard therapy compared to standard therapy alone.
Rett Syndrome Patient Dies in Neurogene Phase I/II Trial After High Dose of Gene Therapy
The patient died from complications linked to a rare hyperinflammatory syndrome associated with exposure to high doses of the AAV therapy delivery vehicle.
FDA Approves Roche CDx Test for Use With Jazz Pharmaceuticals Drug in Biliary Tract Cancer
The approval is for a new indication for Roche's existing Pathway HER2 (4B5) test and is intended to identify patients with HER2-positive biliary tract cancer.